Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
ObjectiveThis study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China.Materials and methodsCancer drugs marketed before June 30th, 2021 with publicly available technical review reports for application of...
Saved in:
Main Authors: | Kexin Ling (Author), Huli Qin (Author), Yiman Feng (Author), Hongxi Che (Author), Jinxi Ding (Author), Wei Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China
by: Jiaming Li, et al.
Published: (2024) -
Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions
by: Ye Chen, et al.
Published: (2024) -
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
by: Wenbo Zhu, et al.
Published: (2017) -
The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China
by: Haoye Li, et al.
Published: (2024) -
The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023)